Patritumab deruxtecan

Patritumab deruxtecan (HER3-DXd; U3-1402) is a HER3-targeted antibody-drug conjugate from Daiichi Sankyo and Merck. The most advanced program is Phase 3 HERTHENA-Breast04 (MK-1022-016, NCT07060807, target n=1,000) in previously treated HR+/HER2- metastatic breast cancer [1], with Phase 2 programs in brain and leptomeningeal metastases (breast and NSCLC) [2][3], gastrointestinal cancers, and pediatric solid tumors. Merck paid Daiichi $4 billion upfront in October 2023 plus $1.5 billion in continuation payments to co-develop three deruxtecan-payload ADCs including HER3-DXd (total deal value up to $22 billion) [4]. The commercial pitch rests on HER3 being broadly expressed across solid tumors with no approved HER3-directed drug yet, plus the validated deruxtecan payload class already generating multi-billion-dollar revenue via Enhertu. The overhang: the FDA issued a Complete Response Letter in June 2024 for EGFR-mutated NSCLC (manufacturing inspection issue at a third-party site) [5a], and the sponsors voluntarily withdrew that BLA in May 2025 after the confirmatory HERTHENA-Lung02 Phase 3 failed its overall survival endpoint [5b] - a much harder failure than the earlier CRL narrative implied. Datopotamab deruxtecan (Datroway, same DXd payload, TROP2 target) was FDA-approved in the same HR+/HER2- MBC indication in January 2025, meaning HER3-DXd now enters that market as a follower, not a first-mover [9].

Novel biologic, first-in-class as a HER3-targeted ADC. Most advanced program is Phase 3 HERTHENA-Breast04 (MK-1022-016, NCT07060807) in previously treated HR+/HER2- metastatic breast cancer (recruiting, n=1,000, PFS/OS dual primary endpoints) [1]. The bound trial for this node is NCT05569811 (VALENTINE), a SOLTI-sponsored Phase 2 exploratory study in operable HR+/HER2- disease, so the DB status of Phase 2 reflects that trial rather than the drug's most advanced program. Regulatory history: the FDA issued a CRL on June 26, 2024 for HER3-DXd in EGFR-mutated NSCLC, citing an inspection finding at a third-party manufacturing facility (not efficacy or safety) [5a]. In May 2025, Daiichi and Merck voluntarily withdrew the NSCLC BLA after the confirmatory Phase 3 HERTHENA-Lung02 topline OS did not meet statistical significance [5b]. That is a substantive efficacy failure in NSCLC, not a manufacturing scar; the NSCLC program is effectively paused rather than deferred. No active FDA breakthrough, fast track, or accelerated approval designations could be confirmed for the current breast cancer program in public sources. Next major readouts are HERTHENA-Breast04 (initiated 2025; per typical registration timelines and enrollment target, primary PFS readout is unlikely before 2028-2029, but no Merck guidance has been publicly stated), longer-term durability data from the Pistilli et al. Nat Med 2025 Phase 2 in HR+/HER2- disease [6], TUXEDO-3 CNS updates [2][3], and cross-tumor HERTHENA-PanTumor01 data [7].

HER3 (ERBB3) is one of four HER-family receptors that sit on cell surfaces and sense growth signals. Unlike its cousin HER2, HER3 has essentially no functional kinase activity of its own. It works by pairing up with other HER receptors, mostly HER2 or EGFR, and firing signals through the PI3K/AKT pathway that tell cells to survive and divide. In cancer, tumors exploit HER3 two ways: they upregulate it as an escape route when HER2 or EGFR inhibitors are applied (a documented resistance mechanism to trastuzumab and osimertinib), and many solid tumors express HER3 at baseline without any HER3 mutation. Antibodies against HER3 alone have mostly failed as monotherapy because you cannot really 'inhibit' a receptor with almost no enzyme activity to block. Patritumab deruxtecan sidesteps that entirely by using HER3 as a delivery address rather than a signaling target. The antibody binds HER3 on the cancer cell, gets pulled inside, and a cleavable tetrapeptide linker releases the deruxtecan (DXd) payload. DXd is a topoisomerase I inhibitor. Topoisomerase I is an enzyme that cancer cells (and all dividing cells) use to unwind DNA during replication; blocking it causes lethal DNA breaks. DXd also has a bystander effect: after release inside a HER3-positive cell, it can diffuse into neighboring cells that express less HER3, which matters because tumors are heterogeneous. This is the same payload chemistry powering Enhertu (trastuzumab deruxtecan) and the newly approved Datroway (datopotamab deruxtecan, TROP2-targeted), which established that the delivery-plus-payload model can produce durable responses in HER2-low disease that older ADCs missed [8].

The bound node trial, NCT05569811 (VALENTINE), is a SOLTI-sponsored Phase 2 open-label study in operable HR+/HER2- breast cancer with Ki67 at least 20%, randomized 1:2:2 to multi-agent neoadjuvant chemotherapy versus HER3-DXd, with or without endocrine therapy. Small, exploratory, primarily hypothesis-generating for pathologic response and biomarker work. The commercially decisive trial is Merck-sponsored HERTHENA-Breast04 (MK-1022-016, NCT07060807), a Phase 3 study in HR+/HER2- metastatic breast cancer after prior endocrine therapy and CDK4/6 inhibitor exposure, target enrollment 1,000, primary endpoint progression-free survival, comparator investigator's choice of chemotherapy [1]. TUXEDO-3 is a Phase 2 single-arm study that specifically enrolled patients with active untreated brain metastases from breast cancer and separately from NSCLC, published in Lancet Oncology in 2025 [2][3]. That population is usually excluded from ADC trials, and brain penetration is a known weak spot for large biologics, so any signal there is a real differentiator. The design question for HERTHENA-Breast04 is whether investigator's-choice chemotherapy is a stiff enough bar in a market already reshaped by sacituzumab govitecan, trastuzumab deruxtecan in HER2-low disease, and now Datroway (datopotamab deruxtecan) which received FDA approval in January 2025 for this exact HR+/HER2- setting [9]. If control-arm patients can cross over to those ADCs after progression, an OS win becomes structurally hard to demonstrate even if PFS separates cleanly.

Our model estimates a 8% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 13%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by its light or open-label blinding, more secondary endpoints than usual, and the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Safety: the DXd payload class carries a known interstitial lung disease (ILD) signal. Enhertu's label includes a boxed warning for ILD/pneumonitis. Across patritumab deruxtecan breast cancer studies, treatment-related ILD/pneumonitis has been reported in roughly 6-7% of patients (approximately 6.6% in pooled early breast cohorts), with most events low-grade but including Grade 5 (fatal) cases [6]. Grade 5 means death - ILD fatalities have occurred with both Enhertu and HER3-DXd, which is why proactive monitoring, imaging surveillance, and early corticosteroid intervention are standard of care and will be part of any HER3-DXd label. This is a manageable but not trivial safety liability. Direct competition - Datroway (datopotamab deruxtecan): FDA-approved January 17, 2025 for HR+/HER2- unresectable/metastatic breast cancer after prior endocrine therapy and chemotherapy, based on TROPION-Breast01 (median PFS 6.9 vs 4.9 months for chemo) [9]. Datroway shares the exact same DXd payload as HER3-DXd but targets TROP2 rather than HER3. HERTHENA-Breast04 will read out into a market where Datroway is already the ADC of choice in this line; there is no head-to-head trial planned, so any HER3-DXd approval will be interpreted by payers and NCCN pathways as an alternative to Datroway on sequencing grounds, not as a first-line displacement. If HER3-DXd's PFS delta over chemo is smaller than Datroway's 2.0-month advantage, the commercial case for coverage weakens materially. Regulatory execution: the June 2024 CRL for EGFR-mutated NSCLC was manufacturing-related, but the May 2025 BLA withdrawal was driven by HERTHENA-Lung02 Phase 3 missing its OS endpoint [5b]. That is a genuine efficacy failure, not a paperwork issue, and it removes the NSCLC franchise from the near-term revenue base. Efficacy in HR+/HER2- breast: response rates from the Pistilli et al. Nat Med 2025 Phase 2 [6] are respectable but not overwhelming versus what trastuzumab deruxtecan achieved in HER2-low DESTINY-Breast04. HER3 expression is broader than HER2, and Phase 2 data have shown weak correlation between HER3 expression level and response [7], which is a serious biomarker problem for label negotiation and payer coverage. Trial design risk: PFS in an open-label study against investigator's-choice chemotherapy is a lower bar than OS. Regulators and reimbursement authorities will scrutinize effect magnitude, not just statistical significance.

Watch, do not chase. The strongest commercial thesis for HER3-DXd was as first-in-line HER3-directed therapy after osimertinib failure in EGFR-mutated NSCLC. The June 2024 manufacturing CRL cost time; the May 2025 HERTHENA-Lung02 OS miss cost the franchise [5a][5b]. What remains is a program that has to win in HR+/HER2- metastatic breast in a market where Datopotamab deruxtecan (Datroway) already secured FDA approval in the same indication in January 2025 [9]. Datroway is same payload, different target, and already carries the sequencing high ground; a HER3-DXd approval enters as the second DXd ADC in this line, competing on subgroup performance and safety profile rather than novelty. The core biological question - whether HER3 targeting adds value over what the DXd payload alone can achieve when delivered by any tumor-associated antibody - remains open. Signal to watch: primary readout from HERTHENA-Breast04 (NCT07060807) [1]. A PFS hazard ratio at 0.65 or better with ILD rates at or below the 6-7% breast cancer baseline is a real drug and a franchise; a 0.75-0.85 HR makes the value proposition against Datroway and Enhertu HER2-low hard to defend commercially, especially without head-to-head data. Second signal: whether TUXEDO-3 brain metastasis data translates into label language for CNS-active disease [2][3], which no current breast ADC (including Datroway) owns as a differentiator. Third signal: any Merck update on whether the NSCLC program is abandoned or being redesigned around a new endpoint or subpopulation; as of May 2025, the BLA is withdrawn and no resubmission plan has been publicly disclosed. Commercial context: Merck's roughly $4 billion upfront October 2023 payment (plus $1.5B continuation, up to $22B total value) for three Daiichi ADCs [4] means Merck has strong economic reason to push HER3-DXd across indications regardless of the NSCLC failure. That funding secures execution but does not fix the biology-versus-payload attribution problem or the Datroway sequencing problem. Check back at the next Merck earnings for HERTHENA-Breast04 timing guidance, and at ESMO or SABCS for updated Pistilli-cohort durability data [6].